Risk of Acute Liver Injury in Agomelatine and Other Antidepressant Users in Four European Countries: A Cohort and Nested Case–Control Study Using Automated Health Data Sources

  1. Pladevall, Manel ORCID logo
  2. Pottegård, Anton
  3. Schink, Tania ORCID logo
  4. Reutfors, Johan
  5. Morros, Rosa
  6. Poblador-Plou, Beatriz
  7. Timmer, Antje
  8. Forns, Joan
  9. Hellfritzsch, Maja
  10. Reinders, Tammo
  11. Hägg, David
  12. Giner-Soriano, Maria
  13. Prados-Torres, Alexandra
  14. Cainzos-Achirica, Miguel
  15. Hallas, Jesper
  16. Brandt, Lena
  17. Cortés, Jordi
  18. Aguado, Jaume
  19. Perlemuter, Gabriel
  20. Falissard, Bruno
  21. Castellsagué, Jordi
  22. Jacquot, Emanuelle
  23. Deltour, Nicolas
  24. Perez-Gutthan, Susana

Download
Pladevall-Vila-et-al_2019_Risk of Acute Liver Injury in Agomelatine and Other Antidepressant Users in Four European Countries_A Cohort and Nested Case–Control Study Using Automated Health Data Sources.pdf 785,96KB
WeightNameValue
1000 Titel
  • Risk of Acute Liver Injury in Agomelatine and Other Antidepressant Users in Four European Countries: A Cohort and Nested Case–Control Study Using Automated Health Data Sources
1000 Autor/in
  1. Pladevall, Manel |
  2. Pottegård, Anton |
  3. Schink, Tania |
  4. Reutfors, Johan |
  5. Morros, Rosa |
  6. Poblador-Plou, Beatriz |
  7. Timmer, Antje |
  8. Forns, Joan |
  9. Hellfritzsch, Maja |
  10. Reinders, Tammo |
  11. Hägg, David |
  12. Giner-Soriano, Maria |
  13. Prados-Torres, Alexandra |
  14. Cainzos-Achirica, Miguel |
  15. Hallas, Jesper |
  16. Brandt, Lena |
  17. Cortés, Jordi |
  18. Aguado, Jaume |
  19. Perlemuter, Gabriel |
  20. Falissard, Bruno |
  21. Castellsagué, Jordi |
  22. Jacquot, Emanuelle |
  23. Deltour, Nicolas |
  24. Perez-Gutthan, Susana |
1000 Erscheinungsjahr 2019
1000 LeibnizOpen
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2019-03-04
1000 Erschienen in
1000 Quellenangabe
  • 33(4):383-395
1000 FRL-Sammlung
1000 Copyrightjahr
  • 2019
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s40263-019-00611-9 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441103/ |
1000 Ergänzendes Material
  • https://link.springer.com/article/10.1007%2Fs40263-019-00611-9#SupplementaryMaterial |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • BACKGROUND: Agomelatine is a melatonin receptor agonist and serotonin 5-HT2C receptor antagonist indicated for depression in adults. Hepatotoxic reactions like acute liver injury (ALI) are an identified risk in the European risk management plan for agomelatine. Hepatotoxic reactions have been reported for other antidepressants, but population studies quantifying these risks are scarce. Antidepressants are widely prescribed, and users often have risk factors for ALI (e.g. metabolic syndrome). OBJECTIVE: The goal was to estimate the risk of ALI associated with agomelatine and other antidepressants (fluoxetine, paroxetine, sertraline, escitalopram, mirtazapine, venlafaxine, duloxetine, and amitriptyline) when compared with citalopram in routine clinical practice. METHOD: A nested case–control study was conducted using data sources in Denmark, Germany, Spain, and Sweden (study period 2009–2014). Three ALI endpoints were defined using International Classification of Diseases (ICD) codes: primary (specific codes) and secondary (all codes) endpoints used only hospital discharge codes; the tertiary endpoint included both inpatient and outpatient settings (all codes). Validation of endpoints was implemented. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for current use were estimated for each data source and combined. RESULTS: We evaluated 3,238,495 new antidepressant and 74,440 agomelatine users. For the primary endpoint, the OR for agomelatine versus citalopram was 0.48 (CI 0.13–1.71). Results were also < 1 when no exclusion criteria were applied (OR 0.37; CI 0.19–0.74), when all exclusion criteria except alcohol and drug abuse were applied (OR 0.47; CI 0.20–1.07), and for the secondary (OR 0.40; CI 0.05–3.11) and tertiary (OR 0.79; CI 0.50–1.25) endpoints. Regarding other antidepressants versus citalopram, most OR point estimates were also below one, although with varying widths of the 95% CIs. The result of the tertiary endpoint and the sensitivity analyses of the primary endpoint were the most precise. CONCLUSIONS: In this study, using citalopram as a comparator, agomelatine was not associated with an increased risk of ALI hospitalisation. The results for agomelatine should be interpreted in the context of the European risk minimisation measures in place. Those measures may have induced selective prescribing and could explain the lower risk of ALI for agomelatine when compared with citalopram. Most other antidepressants evaluated had ORs suggesting a lower risk than citalopram, but additional studies are required to confirm or refute these results.
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-9359-6055|https://frl.publisso.de/adhoc/uri/UG90dGVnw6VyZCwgQW50b24=|https://orcid.org/0000-0002-0224-1866|https://frl.publisso.de/adhoc/uri/UmV1dGZvcnMsIEpvaGFu|https://frl.publisso.de/adhoc/uri/TW9ycm9zLCBSb3Nh|https://frl.publisso.de/adhoc/uri/UG9ibGFkb3ItUGxvdSwgQmVhdHJpeg==|https://frl.publisso.de/adhoc/uri/VGltbWVyLCBBbnRqZQ==|https://frl.publisso.de/adhoc/uri/Rm9ybnMsIEpvYW4=|https://frl.publisso.de/adhoc/uri/SGVsbGZyaXR6c2NoLCBNYWph|https://frl.publisso.de/adhoc/uri/UmVpbmRlcnMsIFRhbW1v|https://frl.publisso.de/adhoc/uri/SMOkZ2csIERhdmlk|https://frl.publisso.de/adhoc/uri/R2luZXItU29yaWFubywgTWFyaWE=|https://frl.publisso.de/adhoc/uri/UHJhZG9zLVRvcnJlcywgQWxleGFuZHJh|https://frl.publisso.de/adhoc/uri/Q2Fpbnpvcy1BY2hpcmljYSwgTWlndWVs|https://frl.publisso.de/adhoc/uri/SGFsbGFzLCBKZXNwZXI=|https://frl.publisso.de/adhoc/uri/QnJhbmR0LCBMZW5h|https://frl.publisso.de/adhoc/uri/Q29ydMOpcywgSm9yZGk=|https://frl.publisso.de/adhoc/uri/QWd1YWRvLCBKYXVtZQ==|https://frl.publisso.de/adhoc/uri/UGVybGVtdXRlciwgR2FicmllbA==|https://frl.publisso.de/adhoc/uri/RmFsaXNzYXJkLCBCcnVubw==|https://frl.publisso.de/adhoc/uri/Q2FzdGVsbHNhZ3XDqSwgSm9yZGk=|https://frl.publisso.de/adhoc/uri/SmFjcXVvdCwgRW1hbnVlbGxl|https://frl.publisso.de/adhoc/uri/RGVsdG91ciwgTmljb2xhcw==|https://frl.publisso.de/adhoc/uri/UGVyZXotR3V0dGhhbiwgU3VzYW5h
1000 Label
1000 Förderer
  1. Servier |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
  1. Risk of Acute Liver Injury in Agomelatine and Other Antidepressant Users in Four European Countries_A Cohort and Nested Case–Control Study Using Automated Health Data Sources
    Risk of Acute Liver Injury in Agomelatine and Other Antidepressant Users in Four European Countries_A Cohort and Nested Case–Control Study Using Automated Health Data Sources
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Servier |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6415144.rdf
1000 Erstellt am 2019-07-12T11:51:10.837+0200
1000 Erstellt von 266
1000 beschreibt frl:6415144
1000 Bearbeitet von 218
1000 Zuletzt bearbeitet 2022-05-31T15:42:24.195+0200
1000 Objekt bearb. Tue May 31 15:42:23 CEST 2022
1000 Vgl. frl:6415144
1000 Oai Id
  1. oai:frl.publisso.de:frl:6415144 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source